Letter in response to: circulating von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality
- PMID: 34101095
- PMCID: PMC8186348
- DOI: 10.1007/s10456-021-09790-w
Letter in response to: circulating von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality
Conflict of interest statement
PB has previously approached both Sanofi to trial Caplacizumab and Lees pharma to trial Anfibatide in COVID + ve patients. GC, GP, and OJ none relevant.
Comment on
-
Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality.Angiogenesis. 2021 Aug;24(3):505-517. doi: 10.1007/s10456-020-09762-6. Epub 2021 Jan 15. Angiogenesis. 2021. PMID: 33449299 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
